🇺🇸 FDA
Patent

US 9187497

Substituted pyrido[3,2-e]pyrrolo[1,2-a]pyrazines as inhibitors of poly(ADP-ribose)polymerase (PARP)

granted A61KA61K31/4985A61K31/506

Quick answer

US patent 9187497 (Substituted pyrido[3,2-e]pyrrolo[1,2-a]pyrazines as inhibitors of poly(ADP-ribose)polymerase (PARP)) held by Takeda Pharmaceutical Company Limited expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Nov 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K31/4985, A61K31/506, A61K31/53, A61K31/5383